Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Simcere Pharmaceutical Group Limited
先聲藥業集團有限公司
(Incorporated in Hong Kong with limited liability)
(Stock code: 2096)

VOLUNTARY ANNOUNCEMENT

THE CLINICAL TRIAL APPROVAL FOR SIM0712 (STAT6) ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by Simcere Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that SIM0712, an oral small molecule degrader targeting signal transducer and activator of transcription 6 ("**STAT6**") independently developed by the Group, has received the Clinical Trial Approval issued by the National Medical Products Administration (國家藥品監督管理局) of China, and the Group proposes to conduct a clinical trial for the treatment of atopic dermatitis.

ABOUT SIM0712

SIM0712 is an oral small molecule degrader targeting STAT6, independently developed by the Group based on its Proteolysis Targeting Chimera (PROTAC) technology platform. By binding to the SH2 domain of STAT6, SIM0712 induces degradation of the STAT6 protein, thereby blocking interleukin-4 (IL-4) and interleukin-13 (IL-13)-mediated signalling and suppressing related type 2 inflammatory responses. Preclinical studies showed that SIM0712 effectively induced degradation of the STAT6 protein at picomolar concentrations in various disease-relevant human immune cells and stromal cells, with no apparent degradation of other STAT family proteins (STAT1 to STAT5) and CRBN-related substrates, suggesting its high target activity and selectivity. In addition, SIM0712 demonstrated significant anti-inflammatory efficacy in mouse models of atopic dermatitis and asthma, and exhibited favourable pharmacokinetic profiles and a clear pharmacokinetic/pharmacodynamic relationship in rats, dogs and cynomolgus monkeys, supporting its potential for further clinical development. SIM0712 has broad application prospects in type 2 inflammatory diseases such as atopic dermatitis, asthma, chronic obstructive pulmonary disease, eosinophilic oesophagitis and chronic rhinosinusitis with nasal polyps, and has the potential to be developed as a "pipelines in a product".

ABOUT THE GROUP

The Company is an innovation and R&D-driven pharmaceutical company and the Group has established a "State Key Laboratory of Neurology and Oncology Drug Development". The Group focuses on the therapeutic areas of neuroscience, anti-oncology, autoimmune and anti-infection, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of "for patients, for life". Driven by its in-house R&D efforts and synergistic innovation, the Company has established strategic cooperation partnerships with many innovative companies and research institutes.

By order of the Board
Simcere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, November 16, 2026

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director; Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; Mr. TANG Renhong as the non-executive Director; Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.